Extended Data Fig. 3: Antigen stimulation of PBMCs is potentiated by RIPR molecules.
From: Immune receptor inhibition through enforced phosphatase recruitment
a, b, Peptide-pulsed PBMCs (PepMix, JPT) were treated with 1 μM of nivolumab, pembrolizumab, RIPR-PD1 with nivo (N) or pembro (P) scFv and anti-CD45 diabody (anti-CD45-Db#4). CD69 was analysed by flow cytometry and IFNγ was quantified by ELISA. Data are mean ± s.d. from n = 3 biological replicates from 1 representative of 2 independent experiments. c, CFSE-labelled CD8+ human T cells were stimulated with anti-CD3 and anti-CD28 in the presence or absence of nivolumab or RIPR-PD1 at 1 μM. T cell proliferation was analysed by FACS on day 3. Data are mean ± s.d. from n = 4 (untreated and anti-CD3/CD28) or n = 9 (nivolumab and RIPR-PD1) biological replicates from 1 representative of 2 independent experiments.
